News Column

Corgenix Enters into Technology Transfer, Product Development Pact with Mellitus

July 17, 2014

Corgenix Medical Corp. reported a technology transfer and product development agreement with Mellitus of Cambridge, Mass.

Mellitus is a private company that is developing a novel in vitro diagnostic test with potential clinical utility for diabetes.

In its release, Corgenix said the test is based on the measurement of Glycated CD59 (GCD59.)

Under terms of the agreement, Corgenix reports that it will develop a test kit to measure GCD59 for Mellitus' U.S. and European Union commercialization programs. Mellitus' lead product candidate is a test for Gestational Diabetes Mellitus (GDM). GDM is a major cause of peri- and post-natal complications for mothers and babies.

"We're pleased to be working with Mellitus on this groundbreaking project," said Douglass Simpson, Corgenix President and CEO. "This allows us to further demonstrate our capabilities in working with industry partners to establish successful strategic alliances in support of clinical research and product commercialization."

"Mellitus is dedicated to bringing the GCD59 Test to market. We believe that Corgenix' in vitro diagnostic development expertise, quality management system and skilled team will make a very important contribution to the development and success of the Mellitus GCD59 in vitro diagnostic test," said Joyce A. Lonergan, Mellitus CEO and co-founder.

Corgenix Medical Corp. is a worldwide developer and marketer of diagnostic test kits.

More information and complete details:

((Comments on this story may be sent to

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Manufacturing Close - Up

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters